CLEVELAND, Ohio –Sangrail Biologics, a clinical-stage gene therapy company focused on restoring life’s blueprint for children with rare genetic diseases, announced the launch of the company today and highlighted the company’s lead clinical asset, SNG-101 (f.k.a. ABO-101), a potential first-in-class AAV gene therapy designed to treat the underlying cause of...

GAITHERSBURG, Md. — Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating pegsebrenatide (NLY01), Neuraly’s long-acting GLP1 receptor agonist, for the potential treatment of patients with multiple sclerosis (MS). Multiple sclerosis...

FOSTER CITY, Calif. — GLP-1 medicines are being prescribed for weight loss at a scale the healthcare system has never managed before. Clinicians can measure weight loss. What they still cannot see, in any scalable, non-invasive way, is which patients are biologically positioned to respond before treatment begins, or how...